Prevalence and risk factors of M tuberculosis infection in young people across 14 communities in Zambia and South Africa.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
12
2022
accepted:
31
07
2023
medline:
29
9
2023
pubmed:
29
9
2023
entrez:
29
9
2023
Statut:
epublish
Résumé
From 2018-2021 the TB Reduction through Expanded Antiretroviral Treatment and TB Screening (TREATS) project took place in 21 Zambian and South African communities. The TREATS Incidence of TB Infection Cohort Study was conducted in adolescents and young people (AYP), aged 15-24 years in 14 communities. We describe the baseline prevalence and risk factors of Mycobacterium tuberculosis (M. tuberculosis) infection among this cohort and explore the quantitative QFT-Plus interferon gamma (IFN-γ) responses. A random sample of approximately 300 AYP per community were recruited and information on TB/HIV risk factors, TB symptoms and social mixing patterns collected. QuantiFERON TB Gold Plus assay (QFT-Plus) was used to detect M. tuberculosis infection, following manufacturer's instructions. Logistic regression was used to determine factors associated with infection. 5577 eligible AYP were invited to participate across both countries, with 4648 enrolled. QFT-Plus results were available for 4529: 2552(Zambia) and 1977(South Africa). Overall, 47.6% (2156/4529) AYP had positive QFT-Plus results, the prevalence of infection in South Africa being twice that in Zambia (64.7% (1280/1977) vs 34.3% (867/2552) p<0.001). Infection was associated with age, household contact with TB and alcohol in Zambia but showed no associations in South Africa. The antigen tube differential (TB2-TB1>0.6 IU/ml) of the assay at baseline showed no evidence of association with recent TB exposure. The high prevalence of infection in AYP warrants urgent action to address TB control, especially in South Africa. Further research is required to delineate antigen tube responses of the QFT-Plus assay more precisely to fully realise the benefit of the additional TB2 tube in high TB/HIV burden settings.
Sections du résumé
BACKGROUND
BACKGROUND
From 2018-2021 the TB Reduction through Expanded Antiretroviral Treatment and TB Screening (TREATS) project took place in 21 Zambian and South African communities. The TREATS Incidence of TB Infection Cohort Study was conducted in adolescents and young people (AYP), aged 15-24 years in 14 communities. We describe the baseline prevalence and risk factors of Mycobacterium tuberculosis (M. tuberculosis) infection among this cohort and explore the quantitative QFT-Plus interferon gamma (IFN-γ) responses.
METHODS AND FINDINGS
RESULTS
A random sample of approximately 300 AYP per community were recruited and information on TB/HIV risk factors, TB symptoms and social mixing patterns collected. QuantiFERON TB Gold Plus assay (QFT-Plus) was used to detect M. tuberculosis infection, following manufacturer's instructions. Logistic regression was used to determine factors associated with infection. 5577 eligible AYP were invited to participate across both countries, with 4648 enrolled. QFT-Plus results were available for 4529: 2552(Zambia) and 1977(South Africa). Overall, 47.6% (2156/4529) AYP had positive QFT-Plus results, the prevalence of infection in South Africa being twice that in Zambia (64.7% (1280/1977) vs 34.3% (867/2552) p<0.001). Infection was associated with age, household contact with TB and alcohol in Zambia but showed no associations in South Africa. The antigen tube differential (TB2-TB1>0.6 IU/ml) of the assay at baseline showed no evidence of association with recent TB exposure.
CONCLUSION
CONCLUSIONS
The high prevalence of infection in AYP warrants urgent action to address TB control, especially in South Africa. Further research is required to delineate antigen tube responses of the QFT-Plus assay more precisely to fully realise the benefit of the additional TB2 tube in high TB/HIV burden settings.
Identifiants
pubmed: 37773934
doi: 10.1371/journal.pgph.0002077
pii: PGPH-D-22-02005
pmc: PMC10540968
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0002077Informations de copyright
Copyright: © 2023 Amofa-Sekyi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Infect. 2019 Apr;78(4):299-304
pubmed: 30707912
Trop Med Int Health. 2018 Apr;23(4):375-390
pubmed: 29432669
Open Forum Infect Dis. 2020 Nov 11;8(1):ofaa520
pubmed: 33511219
BMC Public Health. 2009 Dec 05;9:450
pubmed: 19961618
Eur Respir J. 2018 Feb 21;51(2):
pubmed: 29467206
Elife. 2021 Nov 25;10:
pubmed: 34821551
Clin Infect Dis. 2022 Sep 14;75(5):842-848
pubmed: 34984431
J Clin Microbiol. 2017 Jun;55(6):1650-1657
pubmed: 28298455
Am J Respir Crit Care Med. 2021 Jan 15;203(2):168-174
pubmed: 33197210
PLoS One. 2023 Mar 15;18(3):e0282125
pubmed: 36920991
Int J Tuberc Lung Dis. 2017 Jun 1;21(6):690-696
pubmed: 28482964
Tuberculosis (Edinb). 2018 Jan;108:136-142
pubmed: 29523314
J Acquir Immune Defic Syndr. 2022 Jan 1;89(1):98-107
pubmed: 34629414
PLoS One. 2011 Apr 04;6(4):e18206
pubmed: 21483746
PLoS One. 2013;8(4):e58689
pubmed: 23560039
BMC Infect Dis. 2014 Apr 23;14:221
pubmed: 24758715
N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
PLoS Med. 2020 Apr 2;17(4):e1003067
pubmed: 32240156
Scand J Immunol. 2016 Apr;83(4):255-66
pubmed: 26808160
Respir Med. 2021 Aug-Sep;185:106508
pubmed: 34171790
BMC Public Health. 2008 Aug 14;8:289
pubmed: 18702821
Trials. 2014 Feb 13;15:57
pubmed: 24524229
Am J Respir Crit Care Med. 2013 Jan 15;187(2):206-11
pubmed: 23103734
Diagn Microbiol Infect Dis. 2013 Mar;75(3):277-81
pubmed: 23276770
Int J Tuberc Lung Dis. 2011 Mar;15(3):331-6
pubmed: 21333099
Eur Respir J. 2016 Nov;48(5):1411-1419
pubmed: 27390280
Tuberculosis (Edinb). 2017 Sep;106:38-43
pubmed: 28802403
Lancet Infect Dis. 2016 Feb;16(2):227-38
pubmed: 26867464
Front Immunol. 2018 Dec 13;9:2946
pubmed: 30619306
AIDS. 1997;11 Suppl B:S115-23
pubmed: 9416373
Am J Epidemiol. 2016 Jan 15;183(2):156-66
pubmed: 26646292
Microbiol Spectr. 2021 Dec 22;9(3):e0097221
pubmed: 34756079